2018年4期
刊物介紹
Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics: ● Cancer epigenetics ● Cancer stem cell ● Improved in vivo and in vitro cancer models ● Cancer prevention and epidemiology ● Biomarkers for predicting drug response ● Mechanism of drug sensitivity and resistance ● New approaches for cancer detection and diagnosis ● Oncology clinical trials ● Targeted therapy ● Multidisciplinary treatment for cancer Author benefits: ● Easy online submission via Editorial Manager ● Efficient and professional peer-review by expert referees from around the world ● Rapid pre-print online publication ● No charge for publication and Open Access ● International visibility - the journal is available free online
Cancer Biology & Medicine
- Aberrant expression of enzymes regulating m6A mRNA methylation: implication in cancer
- Advances in isolation and detection of circulating tumor cells based on microfluidics
- G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future
- Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
- PKM2 promotes reductive glutamine metabolism
- Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway
- A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy
- Five-CpG-based prognostic signature for predicting survival in hepatocellular carcinoma patients
- PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
- Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
- Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective singlecenter randomized study
- Multidisciplinary team for the diagnosis and treatment of 2 cases of primary intestinal yolk sac tumor
- 2017 Chinese expert consensus on the clinical application of serum marker for thyroid cancer
- Erratum to Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients